Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Christian Homsy, Chief Executive Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 4:30 p.m. ET in New York, NY.

A live audio webcast of the presentation is available here, where it will be archived for approximately 90 days.

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

Letter to Shareholders - December 2017

Next News

Letter to Shareholders - December 2017